Source: Annual Congress 2006 - Lung cancer biology and chemosensitivity
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
A. M. Ruppert, M. Beau-Faller, A. Mechine, E. Guerin, M. Legrain, A. Schneider, B. Mennecier, G. Massard, J. M. Wihlm, A. Gaub, P. Oudet, E. Quoix (Strasbourg, France). Molecular epidemiology in non small cell lung cancer (NSCLC) tumors: implication of gender and histological features. Eur Respir J 2006; 28: Suppl. 50, 2010

Member's Comments

No comment yet.

Related content which might interest you: Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma Year: 2006 Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019 Influence of histological subtypes of bronchioloalveolar carcinoma on prognosis and treatment Source: Annual Congress 2006 - Prognostic factors in lung cancer Year: 2006 Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 Composite anatomical–clinical–molecular prognostic model in nonsmall cell lung cancer Source: Eur Respir J 2011; 37: 136-142 Year: 2011 Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy Source: Eur Respir J 2012; 39: 1437-1442 Year: 2012 Should there be a specific management for large cell neuroendocrine carcinoma? Source: Annual Congress 2005 - Neuroendocrine tumours of the lung Year: 2005 Potential diagnostic markers in bronquial fluid of patients with non small cell lung cancer (NSCLC) Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications Source: Eur Respir J 2009; 33: 127-133 Year: 2009 Validation and comparison of several published prognostic systems for patients with small cell lung cancer Source: Eur Respir J 2011; 38: 657-663 Year: 2011 Prevalence of silent brain metastasis (BM) in the initial staging of non-small cell lung carcinoma (NSCLC) Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011 Are there any peculiarities in tumour behavior and different tumour markers expression in nonsmall cell lung cancer? Source: Eur Respir J 2001; 18: Suppl. 33, 232s Year: 2001 Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Molecular biologic characterization of operated non-small cell lung cancer according to smoking history Source: Annual Congress 2008 - Risk assessment and treatment of complications in thoracic surgery patients Year: 2008 Treatment of extensive-stage small cell lung carcinoma: current status and future prospects Source: Eur Respir J 2010; 35: 202-215 Year: 2010 BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers Source: Eur Respir J 2015; 45: 1403-1414 Year: 2015 Clinical, histological and molecular characteristics of lung cancer in patients under 30 years-old. Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Significance of expression of TGF-β in pulmonary metastasis in non-small cell lung cancer tissues Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 A novel biologic classification of non-small cell lung cancer Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005